Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics is a clinical-stage oncology company whose lead product (lifileucel / Amtagvi) is a personalized tumor-infiltrating lymphocyte (TIL) therapy — the patient's own immune cells expanded outside the body and infused back to fight melanoma and, increasingly, other solid tumors. The stock has more than tripled over the last twelve months and just cleared the top quintile of its 52-week range on real news.

• The commercial ramp is showing up in the print: Q1 revenue grew 45% year-over-year to $71M, and consensus models $362M for FY26 — that's still tiny by biotech-mega-launch standards, but it's the fastest-scaling personalized-cell-therapy launch in oncology so far.
• The regulatory story just widened: Fast Track designation for lifileucel in soft-tissue sarcoma opens a second real indication for the same manufacturing pipeline, which is what a personalized-cell-therapy business needs to justify its infrastructure cost — one indication doesn't fill the Philadelphia plant, three or four might.
• The short-interest setup is combustible: roughly 102M shares short is treated in the crowd as fuel rather than warning, and every incremental catalyst (ESMO data, NSCLC readout, TD Cowen $10 PT bump) pours borrow-side pressure on a stock that's already 47% above its 50-day moving average.
• Insider activity is only tax-withholding (F-InKind) share surrenders — that's officers meeting an obligation, not conviction; there's no open-market buying to add to the case, which for a name that just tripled is worth naming.

The path if it works is a clean NSCLC or sarcoma readout at ESMO plus a Q3 print that confirms the commercial ramp — the stock keeps compounding on shorts covering and multiple expansion on visible profitability by FY28. What breaks the run is a soft ESMO data point or a melanoma reimbursement snag that reminds buyers this is a highly complex personalized-cell business — that's when 259% one-year gains give back quickly.